COCP
Cocrystal Pharma, Inc.
Key Financials
Net Income
$-8831000
↑ 49.5%
Revenue
$2.0M
0.0%
Total Assets
$9.7M
↓ 27.8%
Gross Profit
$7.2M
↑ 168.9%
EPS (Diluted)
$-0.78
↑ 54.7%
Total Liabilities
$3.4M
↓ 14.0%
Cash & Equivalents
$7.0M
↓ 28.8%
Shareholders' Equity
$6.3M
↓ 33.5%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 9/9/2026 | View on SEC |
| 3 | 8/21/2026 | View on SEC |
| 8-K | 8/18/2026 | View on SEC |
| 8-K | 8/17/2026 | View on SEC |
| 10-Q | 8/13/2026 | View on SEC |
| SCHEDULE 13D | 8/7/2026 | View on SEC |
| SCHEDULE 13D/A | 8/7/2026 | View on SEC |
| 4 | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 8-K | 8/3/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | COCP |
| Company Name | Cocrystal Pharma, Inc. |
| CIK | 1412486 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (786) 459-1831 |